Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ACTU Actuate Therapeutics	$5.96 +2.4%	$9.14	$4.01 ▼ $11.99	$116.94M	N/A	55,946 shs	966,466 shs
ADCT ADC Therapeutics	$2.71 +0.2%	$2.35	$1.05 ▼ $4.13	$268.28M	1.95	595,834 shs	2.83 million shs
NKTX Nkarta	$1.66 -4.0%	$1.87	$1.31 ▼ $8.23	$117.79M	0.72	1.03 million shs	625,328 shs
VNRX VolitionRx	$0.84 -3.5%	$0.56	$0.40 ▼ $0.94	$86.30M	1.07	204,228 shs	139,410 shs

7 Stocks That Could Be Bigger Than Tesla, Nvidia, and Google

Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ACTU Actuate Therapeutics	0.00%	-20.21%	-47.54%	-11.96%	+595,999,900.00%
ADCT ADC Therapeutics	0.00%	-2.17%	-12.74%	+92.53%	-14.40%
NKTX Nkarta	0.00%	-6.21%	-5.41%	-9.78%	-71.91%
VNRX VolitionRx	0.00%	-8.95%	+66.54%	+46.94%	+38.46%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ACTU Actuate Therapeutics	2.0068 of 5 stars	3.5	0.0	2.6	1.7	0.0
ADCT ADC Therapeutics	1.8018 of 5 stars	3.5	2.0	1.1	0.8	0.6
NKTX Nkarta	2.2222 of 5 stars	3.6	1.0	2.6	1.7	0.6
VNRX VolitionRx	1.6349 of 5 stars	3.5	0.0	0.6	2.5	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ACTU Actuate Therapeutics	3.00	Buy	$20.50	243.96% Upside
ADCT ADC Therapeutics	3.00	Buy	$7.75	186.51% Upside
NKTX Nkarta	3.13	Buy	$14.33	763.45% Upside
VNRX VolitionRx	3.00	Buy	$3.50	317.81% Upside

Current Analyst Ratings Breakdown

Latest VNRX, ADCT, NKTX, and ACTU Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/20/2025	ADCT ADC Therapeutics	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Outperform ➝ Moderate Buy	$8.00 ➝ $5.00
6/13/2025	ADCT ADC Therapeutics	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$7.00 ➝ $10.00
6/10/2025	NKTX Nkarta	Mizuho Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$16.00 ➝ $14.00
6/10/2025	VNRX VolitionRx	Jones Trading Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy	$3.00
6/3/2025	ACTU Actuate Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy	$20.00
5/15/2025	ADCT ADC Therapeutics	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform	$8.00 ➝ $8.00
5/15/2025	NKTX Nkarta	William Blair Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Market Perform
5/15/2025	NKTX Nkarta	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$11.00 ➝ $10.00
4/30/2025	VNRX VolitionRx	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$5.00 ➝ $5.00
4/22/2025	ACTU Actuate Therapeutics	Craig Hallum Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$21.00
4/9/2025	NKTX Nkarta	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$11.00 ➝ $11.00

(Data available from 6/30/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ACTU Actuate Therapeutics	N/A	N/A	N/A	N/A	$0.01 per share	N/A
ADCT ADC Therapeutics	$70.84M	3.79	N/A	N/A	($2.10) per share	-1.29
NKTX Nkarta	N/A	N/A	N/A	N/A	$5.78 per share	N/A
VNRX VolitionRx	$1.31M	65.96	N/A	N/A	($0.11) per share	-7.62

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ACTU Actuate Therapeutics	-$27.28M	N/A	0.00	∞	N/A	N/A	N/A	-339.73%	N/A
ADCT ADC Therapeutics	-$157.85M	-$1.45	N/A	N/A	N/A	-197.64%	N/A	-45.57%	8/5/2025 (Estimated)
NKTX Nkarta	-$108.79M	-$1.51	N/A	N/A	N/A	N/A	-26.64%	-21.62%	8/12/2025 (Estimated)
VNRX VolitionRx	-$35.32M	-$0.27	N/A	∞	N/A	-2,321.14%	N/A	-163.39%	N/A

Latest VNRX, ADCT, NKTX, and ACTU Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/15/2025	Q1 2025	ACTU Actuate Therapeutics	-$0.26	-$0.32	-$0.06	-$0.32	N/A	N/A
5/14/2025	Q1 2025	ADCT ADC Therapeutics	-$0.38	-$0.36	+$0.02	-$0.36	$17.71 million	$23.03 million
5/14/2025	Q1 2025	NKTX Nkarta	-$0.44	-$0.43	+$0.01	-$0.43	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ACTU Actuate Therapeutics	N/A	N/A	N/A	N/A	N/A
ADCT ADC Therapeutics	N/A	N/A	N/A	N/A	N/A
NKTX Nkarta	N/A	N/A	N/A	N/A	N/A
VNRX VolitionRx	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ACTU Actuate Therapeutics	N/A	0.46	0.46
ADCT ADC Therapeutics	N/A	4.46	4.16
NKTX Nkarta	N/A	14.48	14.48
VNRX VolitionRx	N/A	0.22	0.22

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ACTU Actuate Therapeutics	N/A
ADCT ADC Therapeutics	41.10%
NKTX Nkarta	80.54%
VNRX VolitionRx	8.09%

Insider Ownership

Company	Insider Ownership
ACTU Actuate Therapeutics	69.34%
ADCT ADC Therapeutics	5.40%
NKTX Nkarta	8.40%
VNRX VolitionRx	10.40%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ACTU Actuate Therapeutics	10	19.62 million	6.02 million	N/A
ADCT ADC Therapeutics	310	99.18 million	93.82 million	Optionable
NKTX Nkarta	140	70.96 million	65.00 million	Optionable
VNRX VolitionRx	80	103.02 million	80.80 million	Optionable

VNRX, ADCT, NKTX, and ACTU Headlines

Recent News About These Companies

Volition Announces MARS Consortium Clinical Study Suggests Nu.Q® H3.1. Concentrations are Closely Associated with Sepsis and Organ Failure

June 12, 2025 | prnewswire.com

Jones Trading Initiates Coverage of VolitionRx (VNRX) with Buy Recommendation

June 11, 2025 | msn.com

VolitionRx (NYSE:VNRX) Coverage Initiated at Jones Trading

June 10, 2025 | marketbeat.com

VolitionRx director Guy Innes buys $10,772 in common stock

June 5, 2025 | investing.com

Insider Buying: VolitionRx Limited (NYSE:VNRX) Director Buys 20,000 Shares of Stock

June 5, 2025 | insidertrades.com

Volition Announces Two Oral Presentations at Asian Meeting of Animal Medicine Specialties

June 4, 2025 | prnewswire.com

VolitionRx Limited (NYSE:VNRX) Director Buys $10,800.00 in Stock

June 4, 2025 | marketbeat.com

VolitionRX shares hold as Benchmark maintains rating

May 21, 2025 | uk.investing.com

VolitionRx Limited (AMEX:VNRX) Q1 2025 Earnings Call Transcript

May 20, 2025 | msn.com

Insider Buying: VolitionRx Limited (NYSE:VNRX) Insider Acquires 50,000 Shares of Stock

May 20, 2025 | insidertrades.com

VolitionRx Limited Announces Successful Detection of Nucleosomes in Cats

May 19, 2025 | prnewswire.com

VolitionRX aims for cash flow neutrality in 2025 as human diagnostics licensing advances

May 16, 2025 | msn.com

VolitionRX Limited (VNRX) Q1 2025 Earnings Call Transcript

May 16, 2025 | seekingalpha.com

VolitionRx Limited Announces First Quarter 2025 Financial Results and Business Update

May 15, 2025 | prnewswire.com

VolitionRx Limited Schedules First Quarter 2025 Earnings Conference Call and Business Update

May 12, 2025 | prnewswire.com

VolitionRX Limited: Outlines broad strategy to become the 'NETs company' worldwide through licensing and updates progress of Nu.Q® NETs test adoption

May 7, 2025 | prnewswire.com

VolitionRX Limited: Revolutionizing the diagnosis and monitoring of life-altering diseases for both humans and animals in multi-billion dollar markets

April 29, 2025 | prnewswire.com

VolitionRx enters new sales agreement, terminates old one

April 24, 2025 | investing.com

VolitionRx initiated with a Buy at H.C. Wainwright

April 8, 2025 | markets.businessinsider.com

HC Wainwright & Co. Initiates Coverage of VolitionRx (VNRX) with Buy Recommendation

April 8, 2025 | msn.com

Earnings call transcript: VolitionRx revenue beats forecast in Q4 2024

April 2, 2025 | investing.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

VNRX, ADCT, NKTX, and ACTU Company Descriptions

Actuate Therapeutics NASDAQ:ACTU

$5.96 +0.14 (+2.41%)

Closing price 06/27/2025 04:00 PM Eastern

Extended Trading

$6.80 +0.84 (+14.01%)

As of 05:27 AM Eastern

Actuate Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies for the treatment of cancers. The company's lead product candidate is Elraglusib Injection, a novel glycogen synthase kinase-3 inhibitor to treat metastatic pancreatic ductal adenocarcinoma. It also develops Elraglusib for the treatment of Ewing sarcoma, metastatic melanoma, and colorectal cancer. The company was formerly known as Apotheca Therapeutics, Inc. and changed its name to Actuate Therapeutics, Inc. in October 2015. The company was incorporated in 2015 and is based in Fort Worth, Texas.

ADC Therapeutics NYSE:ADCT

$2.70 +0.01 (+0.19%)

Closing price 06/27/2025 03:59 PM Eastern

Extended Trading

$2.74 +0.03 (+1.11%)

As of 05:23 AM Eastern

ADC Therapeutics SA focuses on advancing its proprietary antibody drug conjugate (ADC) technology platform to transform the treatment paradigm for patients with hematologic malignancies and solid tumors. Its flagship product is ZYNLONTA, a CD19-directed ADC, received accelerated approval from the U.S. Food and Drug Administration and conditional approval from the European Commission for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL) after two or more lines of systemic therapy. The company is also seeking to continue expanding ZYNLONTA into international markets and into earlier lines of DLBCL and indolent lymphomas, including follicular lymphoma (FL) and marginal zone lymphoma (MZL) as a single agent and in combination through its LOTIS-5 confirmatory Phase 3 clinical trial and LOTIS-7 Phase 1b clinical trial, as well as through investigator-initiated trials (IITs). In addition, it is investigating a CD-22 targeted compound, ADCT-602 that is in a Phase 1/2 investigator-initiated study in relapsed or refractory B-cell acute lymphoblastic leukemia. Further, its clinical-stage pipeline consists of ADCT-601 (mipasetamab uzoptirine) targeting AXL as a single agent and/or in combination in sarcoma, pancreatic, and NSCLC, as well as pre-clinical stage pipeline includes a portfolio of next generation investigational ADCs targeting Claudin-6, NaPi2b, PSMA, and other undisclosed targets. The company was incorporated in 2011 and is headquartered in Epalinges, Switzerland.

Nkarta NASDAQ:NKTX

$1.66 -0.07 (-4.05%)

Closing price 06/27/2025 04:00 PM Eastern

Extended Trading

$1.71 +0.05 (+3.01%)

As of 05:21 AM Eastern

Nkarta, Inc., a clinical-stage biopharmaceutical company, develops and commercializes natural killer cell therapies for cancer and autoimmune disease treatment. The company's lead product candidate is NKX019, a chimeric antigen receptor-natural killer (CAR NK) targeting the CD19 antigen that is in Phase 1 clinical trial for the treatment of relapsed/refractory (r/r) non-hodgkin lymphoma, as well as for lupus nephritis. It also develops NKX101, a CAR NK product candidate targeting cells that display NKG2D ligands, which is in Phase I clinical trial for the treatment of r/r acute myeloid leukemia or higher risk myelodysplastic syndromes, as well as for solid tumors. In addition, the company develops NKX070, targeting the CD70 tumor antigen to treat solid and liquid tumors; and NK+T cell therapy for use in the treatment of oncology, autoimmune disease, or infectious disease. It has a research collaboration agreement with CRISPR Therapeutics AG. Nkarta, Inc. was incorporated in 2015 and is based in South San Francisco, California.

VolitionRx NYSE:VNRX

$0.84 -0.03 (-3.49%)

Closing price 06/27/2025 04:00 PM Eastern

Extended Trading

$0.78 -0.05 (-6.29%)

As of 04:54 AM Eastern

VolitionRx Limited, a multi-national epigenetics company, engages in the development of blood tests to help diagnose and monitor a range of cancers, and sepsis and COVID-19 in the United States and internationally. The company offers Nu.Q Vet, a cancer screening test for dogs and other animals; Nu.Q Nets for monitoring the immune system; Nu.Q Cancer for monitoring disease progression, response to treatment and minimal residual disease; Capture-PCR, an isolating and capturing circulating tumor derived DNA from plasma samples for early cancer detection; and Nu.Q Discover, a solution to profiling nucleosomes. VolitionRx Limited is based in Henderson, Nevada.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time